Use of thyroid hormones in hypothyroid and euthyroid patients: A 2020 THESIS* questionnaire survey of members of the Danish Endocrine Society (*Treatment of hypothyroidism in europe by specialists: An international survey)

Riis, Kamilla Ryom; Froelich, Jacob; Hegedüs, Laszlo; Negro, Roberto; Attanasio, Roberto; Nagy, Endre; Papini, Enrico; Perros, Petros; Bonnema, Steen Joop

doi:10.1530/endoabs.73.oc5.2

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, about 60% of participants would consider combination therapy with LT4 + LT3 for patients with normal serum TSH complaining of persistent symptoms suggestive of hypothyroidism, and less frequently, for protracted hypothyroidism. This accords with that seen in a number of other countries (20,28,30,32), while this propensity of recommending combination therapy was least pronounced in Italy (41.4%) and Bulgaria (40%) (17,24).…”

Section: Monitoring Of Thyroid Hormone Treatment and Combination Ther...supporting

confidence: 86%

“…In accordance with current international and local guidelines (5,35), and with the results of all the national THESIS studies published so far (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32), LT4 was the treatment of choice for the treatment of hypothyroidism among LATS members.…”

Section: Discussionmentioning

confidence: 59%

“…Notably, 12% of LATS members considered the use of thyroid hormone treatment in patients with a simple goiter growing over time, compared to more than 40% in several other THESIS publications (15,17,18,20,32). The high percentage of LATS respondents not supporting the use of thyroid hormones for simple goiter is in keeping with guideline recommendations based on evidence that most patients with goiter do not bene t from LT4 suppressive therapy (48) and the potential adverse effects (7).…”

Section: Treating Hypothyroid and Patients With Lt4mentioning

confidence: 80%

“…LATS was invited to participate in an international initiative referred to as THESIS (Treatment of Hypothyroidism in Europe by Specialists an International Survey), which assessed the attitude of experts towards the use of thyroid hormones in hypothyroidism and several euthyroid conditions in 28 countries. So far, 20 national THESIS investigations have been published (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Use of thyroid hormones in hypothyroid and euthyroid patients: a 2022 THESIS questionnaire survey of members of the Latin American Thyroid Society (LATS)

Cassemiro,

Ilera,

Batalles

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose: Inconsistencies in the medical management of hypothyroidism have been reported between endocrinologists in different countries. This study aimed to identify the attitudes of Latin America thyroid specialists towards the use of thyroid hormones. Methods: Online survey of members of the Latin America Thyroid Society. Results:81/446 (18.2%) completed the questionnaire. Levothyroxine (LT4) was the initial treatment of choice for all respondents. 56.8% would consider LT4 use in biochemically euthyroid patients: infertile women with elevated anti-thyroid antibodies (46.9%), resistant depression (17.3%) and growing goiter (12%). Most respondents preferred tablets (39.5%) over liquid formulations (21.0%) or soft gel capsules (22.2%) and would not consider switching formulations in patients with persistent symptoms. 39.5% would never use LT4+liothyronine (LT3) combination therapy in symptomatic euthyroid patients, due to low quality evidence for benefit. 60.5% reported that persistence of symptoms despite normal TSH is rare (below 5% of patients) and its prevalence has been stable over the last five years. Psychosocial factors (84.0%), comorbidities (86.4%) and the patient unrealistic expectation (72.8%) were considered the top three explanations for this phenomenon. Conclusion:LT4 tablets is the treatment of choice for hypothyroidism. A significant proportion of respondents would use LT4 in some groups of euthyroid individuals, contrasting the recommendations of the major clinical practice guideline indications. LT4+LT3 combination treatment in euthyroid symptomatic patients was considered by nearly 50%. Practices based on weak or absent evidence included use of thyroid hormones for euthyroid subjects by 56.8% of respondents and use of LT4 +LT3 treatment by 60.5% of respondents for patients with persistent symptoms. In contrast to many European countries, LATS respondents report a low and unchanged proportion of dissatisfied patients over the last five years.

show abstract

Section: Monitoring Of Thyroid Hormone Treatment and Combination Ther...supporting

confidence: 86%

Section: Discussionmentioning

confidence: 59%

Section: Treating Hypothyroid and Patients With Lt4mentioning

confidence: 80%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Use of thyroid hormones in hypothyroid and euthyroid patients: a 2022 THESIS questionnaire survey of members of the Latin American Thyroid Society (LATS)

Cassemiro,

Ilera,

Batalles

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Use of thyroid hormones in hypothyroid and euthyroid patients: A 2020 THESIS* questionnaire survey of members of the Danish Endocrine Society (*Treatment of hypothyroidism in europe by specialists: An international survey)

Cited by 1 publication

References 0 publications

Use of thyroid hormones in hypothyroid and euthyroid patients: a 2022 THESIS questionnaire survey of members of the Latin American Thyroid Society (LATS)

Use of thyroid hormones in hypothyroid and euthyroid patients: a 2022 THESIS questionnaire survey of members of the Latin American Thyroid Society (LATS)

Contact Info

Product

Resources

About